by Chris on November 10, 2010
Asuragen Reports Notice of Allowance from USPTO Related to the Diagnostic Application of an Important Cancer-Related miRNA
AUSTIN, Texas–(BUSINESS WIRE)–Asuragen, Inc., a leader in the development of molecular diagnostics, announced today that it had received a Notice of Allowance from the United States Patent and Trademark Office (“USPTO”) for claims related to the use of mir-205 as a diagnostic in lung cancer. Human mir-205 has been identified as being highly expressed in lung cancer when compared with its expression in normal lung tissue, and, as a result, is an excellent marker for use as a diagnostic for lung cancer. Asuragen has a broad IP portfolio with over 69 issued and pending patents related to miRNA including some of the earliest functional diagnostic applications for a number of key miRNAs associated with oncology diseases.
“miRNAs are a category of biomarkers whose importance is increasingly being recognized as is evidenced by the explosion in the number of publications regarding miRNAs. We started working on miRNAs in 2002 prior to our selling Ambion and are pleased that the first, of what is a large portfolio of pending patents, are starting to issue,” said Matt Winkler, CEO and CSO of Asuragen. “This allowance from the USPTO highlights the early work we did in the newly emerging field of microRNAs and it supports our continuing development work towards novel miRNA-based molecular diagnostics for cancer.” This follows closely on the heels of a Notice of Allowance received by Yale University for its let7 patent portfolio for which Asuragen is the exclusive licensee in the fields of diagnostics.
(read the entire release… )
Incoming search terms for this article:
by Chris on February 19, 2010
There are several groups making headlines that are studying the mir-29 family.
Rosetta Genomics
Headlines – Joint Study By Rosetta Genomics And NYU Langone Medical Center Identifies Single MicroRNA Biomarker For Prognosis Of Mesothelioma Patients
Single microRNA exhibits potential to forecast outcomes of MPM
The results clearly demonstrate that higher levels of miR-29c* in MPM predict a more favorable prognosis. Not only was the microRNA able to separate MPM patients by time to progression after surgery, but it also stratified these patients by their survival. Furthermore, the study found that over-expression of miR-29c* in mesothelioma cell lines resulted in significantly decreased proliferation, migration, invasion and colony formation.
- Pass HI, Goparaju C, Ivanov S, Donington J, Carbone M, Hoshen M, Cohen D, Chajut A, Rosenwald S, Dan H, Benjamin S, Aharonov R. (2010) hsa-miR-29c* Is Linked to the Prognosis of Malignant Pleural Mesothelioma. Cancer Res [Epub ahead of print]. [abstract]
UT Southwestern Medical Center – Dr. Eric Olson
Headlines – UT Southwestern Researchers Publish Link Between miRNA Dysregulation, Heart Attack
- van Rooij E, Sutherland LB, Thatcher JE, DiMaio JM, Naseem RH, Marshall WS, Hill JA, Olson EN. (2008) Dysregulation of microRNAs after myocardial infarction reveals a role of miR-29 in cardiac fibrosis. Proc Natl Acad Sci USA 105(35), 13027-32. [abstract]
The miR-29 family targets a cadre of mRNAs that encode proteins involved in fibrosis, including multiple collagens, fibrillins, and elastin. Thus, down-regulation of miR-29 would be predicted to derepress the expression of these mRNAs and enhance the fibrotic response. Indeed, down-regulation of miR-29 with anti-miRs in vitro and in vivo induces the expression of collagens, whereas over-expression of miR-29 in fibroblasts reduces collagen expression.
Ohio State University – Dr. Carlo Croce
Headlines – Posted Interview with Carlo Croce of Ohio State University -5/26/2009
The researchers showed that forced expression of MIR29A, MIR29B and MIR29C leads to the re-expression of tumor suppressor genes such as WWOX and FHIT and triggers cell death by apoptosis in lung cancer cell lines, and reduces the size of engrafted tumors by 56 to 94 percent compared with controls. MIR29 is also lost in prostate cancer, and a subset of breast cancers.
- Garzon R, Heaphy CE, Havelange V, Fabbri M, Volinia S, Tsao T, Zanesi N, Kornblau SM, Marcucci G, Calin GA, Andreeff M, Croce CM. (2009) MicroRNA 29b functions in acute myeloid leukemia. Blood 114(26), 5331-41. [abstract]
- Wang H, Garzon R, Sun H, Ladner KJ, Singh R, Dahlman J, Cheng A, Hall BM, Qualman SJ, Chandler DS, Croce CM, Guttridge DC. (2008) NF-kappaB-YY1-miR-29 regulatory circuitry in skeletal myogenesis and rhabdomyosarcoma. Cancer Cell 14(5), 369-81. [abstract]
- Garzon R, Garofalo M, Martelli MP, Briesewitz R, Wang L, Fernandez-Cymering C, Volinia S, Liu CG, Schnittger S, Haferlach T, Liso A, Diverio D, Mancini M, Meloni G, Foa R, Martelli MF, Mecucci C, Croce CM, Falini B. (2008) Distinctive microRNA signature of acute myeloid leukemia bearing cytoplasmic mutated nucleophosmin. Proc Natl Acad Sci U S A 105(10), 3945-50. [abstract]
- Fabbri M, Garzon R, Cimmino A, Liu Z, Zanesi N, Callegari E, Liu S, Alder H, Costinean S, Fernandez-Cymering C, Volinia S, Guler G, Morrison CD, Chan KK, Marcucci G, Calin GA, Huebner K, Croce CM. (2007) MicroRNA-29 family reverts aberrant methylation in lung cancer by targeting DNA methyltransferases 3A and 3B. Proc Natl Acad Sci U S A 104(40), 15805-10. [abstract]
Incoming search terms for this article:
Loading ...
